A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2016
At a glance
- Drugs Dovitinib (Primary) ; Dovitinib
- Indications Colon cancer; Lung cancer; Rectal cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Novartis; Novartis Pharmaceuticals
- 05 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Apr 2014 Results presented at the 105th Annual Meeting of the American Association for Cancer Research.
- 18 Oct 2013 Planned end date changed from 1 Jan 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History